Project Grant R01AI186761
Award Date 9/18/25
Completion Date 8/31/30
Dollars Obligated $897K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- This $854,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), aims to assess post-tuberculosis (TB) lung disease in TB patients with and without HIV coinfection. The project will utilize novel positron emission tomography (PET) imaging techniques, such as 11C-rifampin PET, to longitudinally profile lesional characteristics and antibiotic exposures in animal models...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,136,143 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to study post-tuberculosis lung disease (PTLD) in youth with and without HIV globally. The project will leverage the Tuberculosis Sentinel Research Network (TB-SRN) in 11 countries to establish the prevalence of PTLD in youth, identify modifiable risk factors, and assess the impact on quality of life....
- This Project Grant award of $3,145,850.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The award supports research at The Johns Hopkins University to investigate macrophage senescence as a driver of granuloma failure and necrosis in pulmonary tuberculosis (TB) and TB/HIV coinfection. Key objectives include understanding the role of stress-induced senescence in myeloid...
- This federal Project Grant award of $709,902 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to establish a well-characterized cohort of individuals with post-tuberculosis lung disease (PTLD) in Uganda. The key objectives are to determine whether sex, HIV serostatus, and air pollution exposure are associated with distinct lung function and chest imaging phenotypes of PTLD. The award will support the enrollment of 650 post-TB and 165 non-TB...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $774,881 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to The Johns Hopkins University on February 24, 2025. The grant will support research to investigate the use of pro-apoptotic drugs, such as navitoclax, as host-directed therapies for treating pulmonary tuberculosis (TB). The research aims to evaluate how these drugs impact lung immune response, tissue...
- This $209,408 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports a research project to characterize the role of unconventional T cell subsets in the immune response to Mycobacterium tuberculosis (MTB) infection using a non-human primate model. The goal is to gain a better understanding of these niche T cell populations in the lung granulomas during the early stages of MTB...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $690,538 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Washington for the project "EXPANDING ACCESS AND IMPACT OF TUBERCULOSIS PREVENTIVE THERAPY: COMMUNITY-FRIENDLY DELIVERY AND MONITORING OF TPT TO IMPROVE UPTAKE AND REDUCE TB TRANSMISSION." The project aims to explore new, person-friendly models of tuberculosis preventive therapy (TPT) delivery to...
- The University of Washington received a $188,760 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research to investigate the role of the lung inflammatory environment and cellular milieu in controlling Mycobacterium tuberculosis (MTB) infection and preventing tuberculosis (TB) disease. Specifically, the research will test the hypothesis that interferon gamma-activated...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,922,220 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The grant supports research to advance apoptosis-inducing agents as host-directed therapy for tuberculosis (TB). The research aims to boost host immune responses via the intrinsic apoptosis pathway to reduce Mycobacterium tuberculosis (MTB) growth and enhance the bactericidal activity of...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,546 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to National Jewish Health in Colorado. The grant will fund research to evaluate the efficacy of tuberculosis (TB) treatment regimens by analyzing the transcriptomic patterns of Mycobacterium tuberculosis injury and adaptation during drug treatment. The research aims to develop more reliable preclinical measures of TB treatment...